Author Archives: Admin


A new study published by our partners, the AfricaBP Open Institute, showcases transformative efforts to harness biodiversity genomics and bioinformatics to drive a sustainable African bioeconomy.





The Africa BioGenome Project (AfricaBP) aims to sequence 105,000 non‑human genomes across Africa, spanning plants, animals, fungi, and protozoa, to support food security, conservation, and biotech innovation. To bridge capacity gaps, the AfricaBP Open Institute organized 31 hands‑on regional workshops in 2024 across five geographic regions, engaging participants from over 50 African countries. These sessions trained 401 African researchers in genome sequencing, gene editing, bioinformatics, molecular biology, ethics, and biobanking, strengthening local research infrastructure and skills.





A highlight case study: the proposed “1000 Moroccan Genome Project,” which illustrates economic returns from local genome sequencing. Analysis shows that a US$20 million investment over 10 years could yield US$40 million in discounted benefits and deliver a benefit–cost ratio (BCR) of 3.29—meaning every dollar invested returns more than three dollars in value—particularly across agriculture, R&D, education, and downstream sectors.





Key recommendations emerge: integrate biodiversity genomics and bioinformatics into national bioeconomy strategies, expand capacity‑building initiatives, build regional sequencing hubs, and foster ethical, inclusive data-sharing policies. Strategic investment in these domains positions African nations to capitalize on their unique biodiversity and reclaim ownership of genomic science—a powerful lever toward sustainable development and regional innovation rooted in African knowledge and priorities  .





In short, AfricaBP’s model provides a scalable path for leveraging genomic science to fuel a resilient, inclusive African bioeconomy driven by regional talent and locally generated data. Read more here.







A landmark discovery, scientists have sequenced the genome of a man buried around 4,500–4,800 years ago at Nuwayrat in Middle Egypt, marking the oldest complete genome ever recovered from the region. Likely a potter in his 60s, the man was buried in a sealed ceramic jar carved into rock, a burial that helped preserve his DNA despite Egypt’s harsh climate.





This genome confirms ancient people-to-people contact between Egypt and Mesopotamia, echoing archaeological evidence of shared pottery styles and writing systems. The Nile likely served not just as a trade route for goods and ideas, but for human migration too.





The discovery demonstrates that DNA preservation is possible and important to build a clearer understanding of Africa's genetic history.





Learn more about this research here: https://www.nature.com/articles/d41586-025-02102-y







Although Africa is the most genetically diverse region on Earth, it remains underrepresented in global immunogenetic databases, particularly for high-resolution Human Leukocyte Antigen (HLA) data critical to immune response and vaccine design.





In a new study, researchers analyzed HLA Class I profiles from South Africa, Kenya, Uganda, Rwanda, and Zambia. They found significant genetic differences not only between countries but also among ethnic groups within the same country. These comparisons with African American and European American populations confirmed that Africa’s HLA diversity is too unique for U.S.-based data to guide T-cell vaccine design.





The findings call for urgent investment in Africa-specific immunogenetic data to ensure vaccines are both effective and equitable. As the world pivots to T-cell-inducing vaccines, representing Africa’s true genetic data becomes a global health priority.





Read more about this study here



For the first time, researchers have detected the invasive Anopheles stephensi mosquito in Gayi, a rural area in southern Niger Republic — a country already grappling with one of the world’s highest malaria mortality rates.
Genetic analysis confirmed its presence alongside native malaria vectors such as An. gambiae s.s., An. coluzzii, and An. arabiensis. The coexistence of these species has resulted in elevated biting and transmission rates, aligning with the surge in malaria cases reported in 2024.






Experts warn that without immediate investment in robust surveillance, targeted vector control, and regional collaboration, An. stephensi could spread rapidly across the Sahel and beyond. Its presence poses a serious threat to malaria control efforts, especially in vulnerable regions bordering Niger. Urgent action is needed to contain its spread and mitigate its public health impact across Africa.






Learn more: https://www.nature.com/articles/s41598-025-07389-5



After years of stalled progress, the fight against antibiotic resistance is gaining momentum. Scientists are now exploring new ways to treat infections without relying solely on traditional antibiotics, a major shift that could reshape how we manage bacterial diseases worldwide.






Thanks to support from organizations like CARB-X and GARDP, researchers are pushing forward alternatives that were once considered too risky or radical. These include therapies like bacteriophages (viruses that infect bacteria), enzymes called lysins that break down bacterial walls, and even treatments that adjust the body’s natural microbiome.






Some scientists are testing immune-based approaches and CRISPR technology to target bacteria more precisely. These ideas are still early in development, but the growing investment and interest show a renewed belief that we don’t have to stay trapped in the old cycle of resistance.
The hope is that these innovative treatments, along with better diagnostic tools and smarter trial designs, could one day offer safer, more sustainable ways to fight deadly infections, especially as antibiotic resistance continues to rise.






This shift marks a new chapter in global health, where innovation may finally help turn the tide against superbugs.
Learn more here.







New research from the University of Surrey and the University of Oxford has uncovered a reversible mechanism in TB bacteria that may explain why the disease is so hard to treat.





The study shows that Mycobacterium tuberculosis uses a process called ADP-ribosylation to tag its DNA, allowing it to pause or resume growth—a possible survival tactic against antibiotics and immune attacks. The enzymes DarT and DarG act like a molecular switch: DarT adds the tag and halts replication, while DarG removes it to restart bacterial growth.





This discovery marks the first time DNA modification has been shown to control gene expression and replication in any organism.





By manipulating this system using CRISPRi and ADPr-Seq, scientists were able to track how these tags affect gene activity and cell division, offering a new target for drug development, especially against dormant or slow-growing TB cells. With over 1.25 million deaths annually, breakthroughs like this could reshape how we treat one of the world’s deadliest infectious diseases. Learn more here.







The Moroccan Genome Project (MGP) sequenced 109 Moroccan genomes, uncovering over 27 million genetic variants, including 1.4 million new ones. This research introduces the Moroccan Major Allele Reference Genome (MMARG), providing a more accurate representation of Moroccan genetic diversity compared to global references.





By identifying unique genetic variants, MGP aims to improve precision medicine, addressing healthcare disparities for Moroccans and North Africans, especially in diseases like kidney disease, heart conditions, and diabetes.





This initiative builds on Morocco's rich genetic history and aims to create a more comprehensive genomic reference for North Africa, paving the way for better healthcare and research in the region.





Learn more here







A groundbreaking study on patients from Angola and Cape Verde has significantly expanded our understanding of TNBC in Sub-Saharan Africa. By sequencing both coding and regulatory regions, researchers found a higher somatic mutation burden compared to other global cohorts, with 86% of variants previously unreported.





Key findings include:





17% of mutations likely have damaging effects at the protein level.





20% overlap with gene regulatory regions.





TP53 remains the top driver gene, but novel candidates like TTN, EACAM7, DEFB132, COPZ2, and GAS1 were also identified.





These discoveries highlight the urgent need for more inclusive cancer genomics research, especially across the highly diverse African continent.





Learn more: https://www.nature.com/articles/s41598-025-94707-6 



A new landmark genetic study has uncovered important insights into breast cancer risk among South African women. The research, led by a collaborative team of scientists and published in Nature, used genome-wide association analysis (GWAS) to explore genetic variants linked to breast cancer in this historically underrepresented population.





By analyzing over 3,500 participants (including 2,485 breast cancer cases), the study identified two significant risk loci—one between the UNC13C and RAB27A genes on chromosome 15, and another within the USP22 gene on chromosome 17. These findings mark the first time these regions have been linked to breast cancer in African populations.





Interestingly, the study also found that polygenic risk scores (PRS) developed from European ancestry datasets poorly predicted risk in this group—explaining less than 1% of the variance. This underlines a growing call in the genomics community: the need for African-specific data to create more accurate and equitable tools for disease prediction and prevention.





Ultimately, this research reinforces the importance of diversity in genomic studies and highlights how African biobanks and community-centered research can reshape global health outcomes.





Want to dive deeper into this research?
Read the full article here:
https://www.nature.com/articles/s41467-025-58789-0







MyAfroDNA, a pioneering African genomics and translational research company, officially launched its new facility in Port Harcourt, Nigeria, on April 25, 2025.

Located at No. 3 MyAfroDNA Close, Off Worgumati Street, Tombia Extension GRA, Port Harcourt, the newly inaugurated center will enhance access to ethically sourced African biospecimens, provide cutting-edge molecular and clinical diagnostic services, and offer comprehensive research collaboration support for scientists globally.

The opening ceremony was graced by key dignitaries, community leaders, academia, and healthcare professionals, including Professor Isaac Zeb-Obipi, Vice Chancellor, Rivers State University; His Royal Majesty  Eze Noble Uwoh, King of Igbu Ehuda Kingdom IV; Professor Julian Osuji, Director Regional Centre for Biotechnology and Bioresources Research at the University of Port Harcourt and Co-Chair African BioGenome Project; Mr. Robert Robinson, President, Laboratory Equipment, Thermo Fisher Scientific; Mr. Romeo, State Representative, Medical Laboratory Science Council of Nigeria (MLSCN);  Hon. Adaeze Oreh, Commission of Health Rivers State; Prof. Dike Alikor, CMD RSUTH; Prof Kinikanwo Green, Executive Secretary RSPHCMB.

In his remarks, the Vice Chancellor of Rivers State University emphasized the importance of facilities like MyAfroDNA in global efforts to bridge representation gaps in clinical research. HRM Eze Noble Uwoh also commended MyAfroDNA’s commitment to scientific excellence and community development, especially for forensics research.

About MyAfroDNA:
MyAfroDNA provides access to diverse African biospecimens across several therapeutic areas and supports researchers in diversifying clinical, genomics, and translational research efforts. Our infrastructure houses molecular diagnostic labs, an African biobank, Diagnostics, Paternity & Forensics room, and a virtual Bioinformatics and Data Centre.

Our services include African biobanking, molecular and clinical testing, customized research support, and contract research organization services. By enabling equitable representation in biomedical studies, MyAfroDNA is helping unlock novel insights into public health, genetic medicine, and personalized care.

For more information, please visit www.myafrodna.com or contact us at info@myafrodna.com.